As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Kazia Therapeutics Ltd. The largest reported stake is Chernett Jorey's, at 19.6%. 14 filings are on record since August 5, 2025 (Schedule 13G/A, August 19, 2026).
Sell to companies like Kazia Therapeutics Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Dauntless Investment Group, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 842,340 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-02
- · Reporting person: Chernett Jorey · Sole voting: 2,339,009 · Shared voting: 0 · Sole dispositive: 2,339,009 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-19
- · Reporting person: Ikarian Capital, LLC · Sole voting: 0 · Shared voting: 575,778 · Sole dispositive: 0 · Shared dispositive: 575,778 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Lynwood Capital Management Inc. · Sole voting: 264,980,500 · Shared voting: 0 · Sole dispositive: 264,980,500 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Chernett Jorey · Percent: 18.5% · SCHEDULE 13G/A
Kazia Therapeutics Ltd has 14 Schedule 13D or 13G filings on record since 2025-08-05. 2 holders' latest filing reports 5% or more of american depository shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 19.6% | 2,339,009 | SCHEDULE 13G/A, 2026-08-19 | 2026-08-05 | |
| Dauntless Investment Group, LLC | 5.4% | 842,340 | SCHEDULE 13G/A, 2026-10-02 | 2026-09-25 |
| Ikarian Capital, LLC | 4.9% | 575,778 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Lynwood Capital Management Inc. | 4.6% | 264,980,500 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Alumni Capital LP | 0% | 0 | SCHEDULE 13G/A, 2026-03-30 | 2026-01-30 |
Holding shares or following this stake? See who's behind Kazia Therapeutics Ltd and the warning signs.
Free to see. No signup.
Keep reading
More on Kazia Therapeutics Ltd and the records around it.
Kazia Therapeutics Ltd elsewhere on the record
- Company profile and every filing Dec 2025
- Form D filing Dec 2025
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Lynwood Capital Management Inc. also filed stake reports on 1 other company: Rein Therapeutics, Inc. (Aug 2026)
- Dauntless Investment Group, LLC also filed stake reports on 3 other companies: Azitra, Inc. (Jun 2026), OKYO Pharma Ltd (Feb 2026), FEMASYS INC (Nov 2025)
- Alumni Capital LP also filed stake reports on 12 other companies: reAlpha Tech Corp. (Nov 2026), Sports Entertainment Gaming Global Corp (Nov 2026), NEXALIN TECHNOLOGY, INC. (Aug 2026)
Watch Kazia Therapeutics Ltd
Get an email when Kazia Therapeutics Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kazia Therapeutics Ltd?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kazia Therapeutics Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kazia Therapeutics Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Chernett Jorey | 2,339,009 | 0 | 2,339,009 | 0 | SCHEDULE 13G/A, 2026-08-19 |
| Dauntless Investment Group, LLC | 0 | 0 | 842,340 | 0 | SCHEDULE 13G/A, 2026-10-02 |
| Ikarian Capital, LLC | 0 | 575,778 | 0 | 575,778 | SCHEDULE 13G/A, 2026-08-14 |
| Neil Shahrestani | 0 | 575,778 | 0 | 575,778 | SCHEDULE 13G/A, 2026-08-14 |
| Lynwood Capital Management Inc. | 264,980,500 | 0 | 264,980,500 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Ben Shapiro | 264,980,500 | 0 | 264,980,500 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Lynwood Opportunities Master Fund | 264,980,500 | 0 | 264,980,500 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Kazia Therapeutics Ltd by CUSIP 48669G105 and gives its principal executive office as Three International Towers, Level 24, 300 Barangaroo Avenue, SYDNEY NSW (SCHEDULE 13G/A, 2026-10-02).
What the percentages are based on
See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 5,713,449,734 Ordinary Shares outstanding as of March 12, 2026 as reported by the Issuer in a Form F-3 filed with the SEC on March 18, 2026.Lynwood Capital Management Inc., SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Dauntless Investment Group, LLC | 8.4% | SCHEDULE 13G/A |
| 2025-09-12 | Alumni Capital LP | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Dauntless Investment Group, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-01-23 | Lynwood Capital Management Inc. | 5.4% | SCHEDULE 13G |
| 2026-02-12 | Dauntless Investment Group, LLC | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Ikarian Capital, LLC | 5.1% | SCHEDULE 13G |
| 2026-02-20 | Chernett Jorey | 12.46% | SCHEDULE 13G/A |
| 2026-03-30 | Alumni Capital LP | 0% | SCHEDULE 13G/A |
| 2026-03-31 | Chernett Jorey | 13.9% | SCHEDULE 13G/A |
| 2026-05-27 | Chernett Jorey | 18.5% | SCHEDULE 13G/A |
| 2026-08-14 | Lynwood Capital Management Inc. | 4.6% | SCHEDULE 13G/A |
| 2026-08-14 | Ikarian Capital, LLC | 4.9% | SCHEDULE 13G/A |
| 2026-08-19 | Chernett Jorey | 19.6% | SCHEDULE 13G/A |
| 2026-10-02 | Dauntless Investment Group, LLC | 5.4% | SCHEDULE 13G/A |
Questions about who owns Kazia Therapeutics Ltd
Who owns Kazia Therapeutics Ltd?
On this page, 2 holders' latest ownership filings report 5% or more of Kazia Therapeutics Ltd: Chernett Jorey (19.6%, Schedule 13G/A, filed 2026-08-19) and Dauntless Investment Group, LLC (5.4%, Schedule 13G/A, filed 2026-10-02).
Who are the largest shareholders of Kazia Therapeutics Ltd?
By the share each holder's latest filing reports, the largest holders of Kazia Therapeutics Ltd on this page are Chernett Jorey (19.6%) and Dauntless Investment Group, LLC (5.4%).
When did Chernett Jorey buy into Kazia Therapeutics Ltd?
The filings give report dates, not purchase dates. The earliest filing from Chernett Jorey on this page is the Schedule 13G/A, filed 2026-02-20, reporting 12.46%; its latest, Schedule 13G/A filed 2026-08-19, reports 19.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Kazia Therapeutics Ltd
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 18, 2025 | Form D, private offering | $55.25M sold | Form D page | Source |
| August 14, 2025 | Form D, private offering | $2.05M sold | Form D page | Source |
| January 17, 2025 | Form D, private offering | $2.06M sold | Form D page | Source |
Kazia Therapeutics Ltd: every filing and event
Tools for this story
Each opens in a new tab, filled in for Kazia Therapeutics Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.